Target intelligence / Profile preview

Candida albicans and other pathogenic vaginal microbes

Molecular classification
Other
01

Overview

Candida albicans and other pathogenic vaginal microbes refers to a diverse group of microorganisms, including fungi, bacteria, and protozoa, that cause infections of the female lower reproductive tract. Candida albicans is the most common cause of vulvovaginal candidiasis (VVC), characterized by its ability to transition from a commensal yeast to an invasive hyphal form [1]. Other significant pathogens in this category include Gardnerella vaginalis and various anaerobes associated with bacterial vaginosis (BV), as well as the protozoan Trichomonas vaginalis [2]. These microbes typically cause disease by displacing protective Lactobacillus species, leading to a state of dysbiosis and inflammation [3]. Treatment involves a variety of antimicrobial agents, such as azoles for fungal infections and nitroimidazoles for bacterial or protozoal infections, which target specific metabolic or structural components of the pathogens [4]. Clinical management is often complicated by the formation of biofilms and the increasing prevalence of drug-resistant strains [5].

Other names
Vaginal pathogensVulvovaginal candidiasis pathogensBacterial vaginosis pathogensTrichomonas vaginalisGardnerella vaginalisCandida speciesVaginal microbiotaVaginal dysbiosis pathogens
02

Mechanism of action

Antifungal agents like azoles inhibit the enzyme lanosterol 14-alpha-demethylase, preventing ergosterol synthesis and disrupting fungal cell membrane integrity [4]. Antibacterial and antiprotozoal agents like nitroimidazoles are reduced within the pathogen to form reactive intermediates that cause DNA strand breakage [2]. Polyene antifungals bind directly to ergosterol in the cell membrane, creating pores that lead to leakage of intracellular contents [1].

03

Biological functions

PathogenesisBiofilm formationMicrobial metabolismHost-pathogen interaction
04

Disease associations

InfectionVulvovaginal candidiasisBacterial vaginosisTrichomoniasis
05

Safety considerations

Antimicrobial resistance [5]Disruption of commensal Lactobacillus species [3]Systemic absorption and side effects of antifungals [4]Recurrence of infection [5]Biofilm-mediated persistence [5]
06

Interacting drugs

Fluconazole

8 more in the full profile.

07

Biomarkers

Vaginal pH [2]Whiff test [2]Clue cells [2]Fungal culture [1]Nucleic acid amplification testing (NAAT) [2]

Beyond the preview

Go deeper on Candida albicans and other pathogenic vaginal microbes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Candida albicans and other pathogenic vaginal microbes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call